Top Stock Reports For Microsoft, Royal Dutch Shell & IBM
Zacks Investment Research | Oct 09, 2019 02:54AM ET
Wednesday, October 9, 2019
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Microsoft (MSFT), Royal Dutch Shell (LON:RDSa) (RDS.A) and IBM (IBM). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see
Microsoft’s shares have outperformed the S&P 500 year to date (33.6% vs. 15.3%). The Zacks analyst believes that Microsoft is benefiting from growing user base of its different applications like Office 365 commercial, Dynamics, Outlook mobile and Teams.
Moreover, Azure’s expanding customer base is a key catalyst. Microsoft’s gaming segment is performing well, primarily driven by a combination of Xbox Live, Game Pass subscriptions and Mixer, which are driving user engagement. Further, acquisitions like PlayFab and GitHub expand Microsoft’s total addressable market and penetration. Additionally, an expanding partner base is notable.
However, projections of a moderating growth rate in commercial cloud gross margin, and OEM Pro and Windows commercial businesses is a headwind. Moreover, competition from the likes of Google (NASDAQ:GOOGL), Apple (NASDAQ:AAPL), Sony and Nintendo is intense.
(You can )
Shares of Royal Dutch Shell have lost 13.2% in the past six months, outperforming the Zacks International Integrated Oil industry’s fall of 16.7%. The Zacks analyst states that company’s cash flow continues to increase, allowing it to cut debt while covering the share buybacks and cash dividend.
As it is, the Anglo-Dutch company's position as a key supplier of liquefied natural gas should drive long-term cash flow growth on attractive opportunities. However, there are worries over a drop in its downstream segment earnings while the company’s poor reserve replacement ratio raises concerns about future production.
Shell's operations in violence-prone regions of Nigeria pose additional risk. Hence, investors are advised to wait for a better entry point.
(You can ).
IBM’s shares have lost 1.5% over the past three months compared with the S&P 500’s decline of 2.9%. The Zacks analyst believes that IBM is benefiting from operating efficiency, cost cutting and lower share count.
Get The News You Want
Moreover, the company’s improving position in the hosted cloud, security and analytics holds promise. The company is also witnessing growth in industry verticals like health as well as key areas of analytics and security. Solid adoption of Watson Health and broad-based growth in Payer, Provider, Imaging and Life Sciences domains, is also noteworthy.
The RedHat acquisition aimed at improving hybrid cloud platform is likely to enhance IBM's prospects. Notably, the company has a positive record of earnings surprises in recent quarters.
However, softness in cognitive solutions and technology & cloud platforms remains a concern. Competition for the Storage hardware segment is stiff. A highly leveraged balance sheet adds to the woes.
(You can ).
Other noteworthy reports we are featuring today include Exxon Mobil (XOM), Thermo Fisher Scientific (TMO) and American Tower (NYSE:AMT) (AMT).
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
Mark Vickery
Senior Editor
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly
Today's Must Read/h6
Featured Reports/h6
The Zacks analyst is bullish about Thermo Fisher's firm growth in end markets categorized by customer type. The Brammer Bio buyout should fortify its position in Gene and Cell Therapy space.
Per the Zacks Analyst, American Tower's efforts to expand its telecom-tower portfolio amid favorable trends in mobile-data usage and rising investments in 5G technology are a strategic fit.
The Zacks analyst expects Yum! Brands' digital initiatives to drive growth.
Per the Zacks Analyst, PSEG's regular investments in infra projects bolsters its growth prospects.
Per the Zacks Analyst, TransDigm strengthens its position in proprietary aerospace components' niche markets, through strategic acquisitions.
Per the Zacks analyst, Altice's strategy of building next-generation fiber network to meet the demand for increasing data speed and support evolving technologies augurs well for future revenue growth.
Per the Zacks Analyst, disciplined acquisition strategy has been a pivotal element for the company's overall growth. It also continues to exhibit strong balance sheet and cash flow generation capacity.
The Zacks analyst is bullish about Thermo Fisher's firm growth in end markets categorized by customer type. The Brammer Bio buyout should fortify its position in Gene and Cell Therapy space.
Per the Zacks Analyst, American Tower's efforts to expand its telecom-tower portfolio amid favorable trends in mobile-data usage and rising investments in 5G technology are a strategic fit.
The Zacks analyst expects Yum! Brands' digital initiatives to drive growth.
Per the Zacks Analyst, PSEG's regular investments in infra projects bolsters its growth prospects.
Per the Zacks Analyst, TransDigm strengthens its position in proprietary aerospace components' niche markets, through strategic acquisitions.
Per the Zacks analyst, Altice's strategy of building next-generation fiber network to meet the demand for increasing data speed and support evolving technologies augurs well for future revenue growth.
Per the Zacks Analyst, disciplined acquisition strategy has been a pivotal element for the company's overall growth. It also continues to exhibit strong balance sheet and cash flow generation capacity.
New Upgrades/h6
The Zacks analyst is impressed with Newmont Goldcorp's efforts to reduce debt and improve efficiency. The company should also benefit from progress in its key growth projects.
Per the Zacks analyst, Newell is smoothly progressing with the execution of its Accelerated Transformation Plan. These efforts will help improve operational performance and enhance shareholder value.
Per the Zacks analyst, the launch of newly approved for Sunosi in July is likely to boost Jazz's sleep franchise which continues to perform well on the back of strong demand for Xyrem.
The Zacks analyst is impressed with Newmont Goldcorp's efforts to reduce debt and improve efficiency. The company should also benefit from progress in its key growth projects.
Per the Zacks analyst, Newell is smoothly progressing with the execution of its Accelerated Transformation Plan. These efforts will help improve operational performance and enhance shareholder value.
Per the Zacks analyst, the launch of newly approved for Sunosi in July is likely to boost Jazz's sleep franchise which continues to perform well on the back of strong demand for Xyrem.
New Downgrades/h6
ExxonMobil warns that weak upstream operations will hurt third-quarter earnings. Scheduled maintenance activities, affecting the firm's downstream unit, intensify the Zacks analyst's concerns.
Per the Zacks analyst, TD Ameritrade's bottom-line remains under pressure due to continued rise in operating expenses due to the company's investments in technology and advice and guidance offerings.
The Zacks analyst is pessimistic about the slowdown in global economy, which is hurting the Express unit's performance. High TNT Express integration expenses are an added concern.
ExxonMobil warns that weak upstream operations will hurt third-quarter earnings. Scheduled maintenance activities, affecting the firm's downstream unit, intensify the Zacks analyst's concerns.
Per the Zacks analyst, TD Ameritrade's bottom-line remains under pressure due to continued rise in operating expenses due to the company's investments in technology and advice and guidance offerings.
The Zacks analyst is pessimistic about the slowdown in global economy, which is hurting the Express unit's performance. High TNT Express integration expenses are an added concern.
undefined Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.